Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pomalidomide Celgene

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

- PMLiVE

Celgene promotes senior EMEA figures

Marie-France Tschudin and Stefano Portolano take on new roles

- PMLiVE

Building a business that is lean and specialised

Tuomo Pätsi on Celgene’s approach to access, marketing and the importance of culture

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

UK flag

UK knows ‘almost nothing’ about pancreatic cancer

Celgene-sponsored survey shows 64% of people know little about the disease

- PMLiVE

Celgene wins orphan drug award at PMEA

Company is recognised for providing early access to Imnovid in multiple myeloma

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

Celgene building

Celgene signs $1bn immunotherapy deal with Sutro

Includes exclusive option to acquire the San Francisco-based biotech

- PMLiVE

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

Will gain access to the biopharma's portfolio of viral infection candidates

- PMLiVE

Celgene’s Otezla gains new US psoriasis approval

FDA backs oral drug in moderate to severe plaque psoriasis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links